No Data
New stock news | Maiwei Bio has submitted its application to the Hong Kong Stock Exchange, with CITIC and Haitong as co-sponsors.
Maiwei Biotech is a pharmaceutical company primarily focused on the independent development of drugs for tumors and age-related diseases, currently in the commercialization stage.
Maiwei Bio (688062.SH): has submitted a Listed in Hong Kong issuance application and published application materials.
Maiwei Biotech (688062.SH) announced that the company has submitted to the Hong Kong Stock Exchange on January 6, 2025...
Mabwell: HK Listing to Help Capital Needs of Business, Promote Sustainable Development
Mabwell: To Find Appropriate Timing for H-Share Issuance
Mabwell (Shanghai) Bioscience: Board Approved Proposal to List on Hong Kong Exchange
Maiwei Biotechnology (688062.SH) plans to jointly invest in a bone health Innovative Drugs project with the Chongqing High-tech Zone Management Committee and others.
Maiwei Biological (688062.SH) announced that the company intends to cooperate with the Chongqing High-tech Industrial Development Zone Management Committee (abbreviated as...
No Data
